Effect of resmetirom or placebo in NASH (MASH) fibrosis patients with<5% or≥5% weight loss and/or on baseline GLP-1 therapy in the MAESTRO-NASH 52-week serial liver biopsy study - Schattenberg, J M (Diabetologie und Stoffwechsel, 2025)